We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Growing demand for weight-loss solutions has catapulted pharmaceutical firms like Eli Lilly (LLY) and Novo Nordisk (NVO) into ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

amycretin led to up to 22% weight loss over 36 weeks, showing a safety profile similar to Novo's semaglutide and Eli Lilly's (NYSE:LLY) tirzepatide. The 125-subject study evaluated the drug's ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Meanwhile, those in the placebo group gained between 1.9% and 2.3%. Novo also tested an oral version of amycretin last year, ...

Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...

The Danish drug company said an experimental weight-loss shot helped patients lose over one-fifth of their bodyweight. Novo's U.S. and [Europe-listed s ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

The yearlong downtrend in obesity drug supplier Novo Nordisk (NVO) is potentially over. Last Friday, Jan. 25, NVO stock gained 8.47% to close at $87.97. The company posted the results of its obesity ...

Shares of Novo Nordisk, which is a leader in the weight-loss drug market with Mounjaro and Zepbound maker Eli Lilly (LLY), had fallen about 23% in the past 12 months entering Friday. Eli Lilly ...